Analysts think HRTX stock price could increase by 135%
Jul 31, 2024, 6:25 AM
-31.56%
What does HRTX do
Heron Therapeutics, headquartered in San Diego, develops pharmaceuticals for acute and oncology care, employing 203 people. Their products include SUSTOL and CINVANTI for chemotherapy-related nausea and ZYNRELEF for pain management.
6 analysts think HRTX stock price will increase by 135.11%. The current median analyst target is $6.63 compared to a current stock price of $2.82. The lowest analysts target is $5.05 and the highest analyst target is $9.45.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
